Molecular Theranostics

Ohio, US · 1 known investors

MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.